Excessive Daytime Sleepiness Clinical Trial
— SOMNOLDOfficial title:
Sleepiness in the Elderly: Validation of the Alternative Epworth Sleepiness Scale ESS-ALT in French
NCT number | NCT05822128 |
Other study ID # | APHP230377 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 28, 2023 |
Est. completion date | October 20, 2023 |
Verified date | November 2023 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The Epworth Sleepiness Scale (ESS) is undoubtedly the most commonly used tool in daily clinical practice to assess daytime sleepiness in patients of all ages by means of a self-administered questionnaire. In elderly subjects, the clinician is often confronted with difficulties in accurately estimating the ESS score and measuring subjective daytime sleepiness. Indeed, according to Onen et al, the ESS tends to underestimate the prevalence of sleep disorders in the geriatric population, mainly due to non-response to problematic items, namely: - Item 3: Sitting, inactive in a public place (cinema, theater, meeting) - Item 8: In a car that has been stopped for a few minutes. In order to overcome this problem, Janine Gronewold's German team has developed and begun work on the validation of an alternative version of the ESS, the ESS-ALT, adapted to the population of interest, in German. The aim of the present work is to adapt the ESS-ALT in French, then to study its correlation with sleep data recorded by nocturnal polysomnography, and among the secondary objectives, to correlate it with sleep latency during iterative sleep latency tests, in order to propose to the clinician a simple, reproducible tool, allowing to measure daytime sleepiness in elderly subjects.
Status | Completed |
Enrollment | 102 |
Est. completion date | October 20, 2023 |
Est. primary completion date | October 19, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: - Patient 65 years of age and older - Consulting for sleep disorders - Enrolled in a social security system or entitled to it - Patient informed and having expressed his non-opposition to participate in the research Exclusion Criteria: - Severe psychiatric or cognitive disorders that do not allow the completion of examinations/questionnaires - Patients who are dependent for all acts of daily life - Patients with a very short life expectancy - Patients under guardianship or curatorship - Patients under AME - Patients whose first language is not French - Patients with visual or cognitive impairments that make reading impossible |
Country | Name | City | State |
---|---|---|---|
France | Hospital Charles Foix | Ivry-sur-Seine | |
France | service des pathologies du sommeil, hôpital Pitié Salpêtrière | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Validation of the alternative Epworth Daytime Sleepiness Scale -ALT adapted to the elderly and geriatric population in French | forward and backward translation" between English and French, and correlation with the ESS sleepiness scale. | 24 hours | |
Secondary | Study of the correlation between the results of the French ESS-ALT and polysomnography data | Statistical comparison to identify the intrinsic validity of the ESS-ALT | 24 hours | |
Secondary | Study of the correlation between the results of the French ESS-ALT and MSLT (Multiple Sleep Latency Test) data | Statistical comparison to identify the intrinsic validity of the ESS-ALT | 24 hours | |
Secondary | intrinsic validity of the ESS-ALT in French | Statistical comparison to identify the intrinsic validity of the ESS-ALT | 24 months | |
Secondary | Study of the correlation between the ESS-ALT cohort in French and the ESS-ALT cohort in Germany | Statistical comparison to identify the intrinsic validity of the French version of ESS-ALT | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05059223 -
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
|
Phase 3 | |
Completed |
NCT04923594 -
Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy
|
Phase 2 | |
Completed |
NCT01072968 -
BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.
|
Phase 3 | |
Completed |
NCT01620554 -
Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)
|
Phase 2 | |
Completed |
NCT01067235 -
Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy
|
Phase 3 | |
Completed |
NCT00642928 -
Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients
|
Phase 2 | |
Completed |
NCT00228566 -
Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
|
Phase 3 | |
Enrolling by invitation |
NCT05113745 -
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy
|
Phase 3 | |
Recruiting |
NCT05939453 -
Impact of Bright Light Therapy on Prader-Willi Syndrome
|
N/A | |
Completed |
NCT01006122 -
A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy
|
Phase 2 | |
Completed |
NCT02720744 -
Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
|
Phase 3 | |
Completed |
NCT03194217 -
BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness
|
Phase 2 | |
Completed |
NCT01067222 -
Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy
|
Phase 3 | |
Completed |
NCT00228553 -
Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness
|
Phase 3 | |
Completed |
NCT04789174 -
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
|
Phase 4 | |
Active, not recruiting |
NCT04886518 -
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1
|
Phase 2 | |
Terminated |
NCT00620659 -
Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015)
|
Phase 2 | |
Completed |
NCT01071876 -
BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS
|
Phase 3 | |
Active, not recruiting |
NCT05458128 -
A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia
|
Phase 3 | |
Completed |
NCT02739568 -
Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA
|
Phase 3 |